SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

H. Lee Moffitt Cancer Center and Research Institute

Status: Completed

Conditions: Coronavirus Infection

Treatments: Diagnostic Test: SARS-CoV-2 Antibody Analysis; Behavioral: Web Based Questionnaire; Diagnostic Test: Weck-cel Swab Collection

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04596579

MCC-20635

Details and patient eligibility

About

The overall goal of this study is to understand the immune response (IgG) to SARS-CoV-2 to fill critical knowledge gaps in the natural history of this virus and to inform the development of future infection mitigation efforts. The study team aims to assess the prevalence of circulating IgG antibodies to SARS-CoV-2 and the factors associated with sero-prevalence. These data will be used to estimate the total population that has been exposed to the virus (asymptomatic and symptomatic), the proportion of the population that may be protected by natural immunity, and the proportion that is susceptible. Data obtained from this research will be shared with the Florida Department of Health.

Enrollment: 1,135 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Resident of Hillsborough County, Florida
• 18 years of age or older
• Currently not exhibiting symptoms of SARS-CoV-2 infection

Trial design

1,135 participants in 4 patient groups

Participants age 18-34

Description:

Up to 300 participants age 18-34 who received an invitation by mail and are free of fever at time of interview.

Treatment:

Behavioral: Web Based Questionnaire

Diagnostic Test: Weck-cel Swab Collection

Diagnostic Test: SARS-CoV-2 Antibody Analysis

Participants age 35-54

Description:

Up to 300 Participants age 35-54 who received an invitation by mail and are free of fever at time of interview.

Treatment:

Behavioral: Web Based Questionnaire

Diagnostic Test: Weck-cel Swab Collection

Diagnostic Test: SARS-CoV-2 Antibody Analysis

Participants age 55-64

Description:

Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.

Treatment:

Behavioral: Web Based Questionnaire

Diagnostic Test: Weck-cel Swab Collection

Diagnostic Test: SARS-CoV-2 Antibody Analysis

Participants 65 and over

Description:

Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.

Treatment:

Behavioral: Web Based Questionnaire

Diagnostic Test: Weck-cel Swab Collection

Diagnostic Test: SARS-CoV-2 Antibody Analysis